INTRODUCTION
Liver transplantation is a worldwide standard treatment for end-stage liver disease and for some specific stages of hepatocellular carcinoma. However, there has been an acute shortage of liver grafts from deceased donors for many years. Subsequently, the dropout of patients due to progression of disease and the mortality rate during the waiting time are both increasing, according to data from the French National Transplantation Agency ("Agence de Biomédecine") ( Table I) . Similar data are reported in North America [1, 2] . This growing gap between the number of deceased donor organs and the number of patients on the waiting list for liver transplantation has motivated the use of other sources of grafts, such as living donor liver transplantation (LDLT).
The principle of LDLT is based on the ability of the liver parenchyma to regenerate. Indeed, the liver is comprised of autonomous vascular territories, allowing the division of the liver into different partial grafts. The effective liver regeneration is possible if 30% of its initial mass is respected, which corresponds on average to 0.5% of the individual's body weight [3] . On the other hand, the necessary mass of liver parenchyma for the recipients is at least 1% of their body weight. Therefore, the right liver is often chosen in order to achieve the receiver needs.
Historically, the first attempt of adult-child LDLT was made by Raia et al. [4] in Brazil in 1988, who described two failed cases despite a successful procedure. The first successful LDLT adult-child (left lobe) was performed in 1989 in Brisbane, Australia to overcome the lack of suitable grafts for pediatric recipients [5] .
The technique was then extended to adult recipients (1993: first successful adult-adult LDLT using a left liver lobe [6] ; 1996: first adult-adult LDLT from a right liver lobe [7] ) in order to solve the shortage of deceased donor grafts and provide a source of grafts in countries where the recovery of deceased J Gastrointestin Liver Dis, June 2018 Vol. 27 No 2: 169-178 donor organs was not possible for organizational or cultural reasons. Using a living donor graft presents several advantages: the programmed and controlled intervention at an optimum time for the recipient, the shorter cold ischemia time and the procurement of a living donor graft with predefined anatomical features and, more importantly, of optimal quality.
The main hindrance in the development of adult-adult LDLT is the risk of morbidity and mortality for donors, which raises legitimate ethical questions [8] . These ethical issues have been carefully considered and discussed by Singer et al. [9] , who proposed the criteria by which donors and recipients should be selected. Because of the risks, this technique remains marginal, accounting only for 1% of all transplants performed in France currently (14 LDLT including 3 for adult recipients) (Table II) . While there was only one center that performed adult LDLT in 1997 in the USA, this number has gradually increased to 38 centers in 2000. The number of adult-to-adult LDLT performed per year increased until the death of a liver donor in 2002 sparked a media furor that seriously compromised the pursuit of LDLT programs in the U.S. and significantly decreased the use of this procedure in the following years [10] .
The aims of our study were to review the series dealing with morbidity and mortality in LDLT and to identify the strategies proposed in the literature for developing LDLT.
SEARCH STRATEGY
We conducted a systematic literature review in order to evaluate the morbidity and mortality of the donor in LDLT, and to assess the new strategies developed to increase LDLT practice.
A computerized search was made using the Medline database from January 2000 to 2017. Data sources were Englishlanguage reports on donor outcome after LDLT. Two searches were conducted: the MeSH terms "liver transplantation" and "morbidity" in combination with keyword "living donor liver transplantation" yielded 138 hits. The MeSH terms "liver transplantation" and "mortality" in combination with keyword "living donor liver transplantation" led to 267 hits. References of retrieved articles were cross-checked to identify additional reports. We excluded duplicate articles and obtained 382 articles about morbidity and/or mortality. Abstracts of relevant articles were reviewed independently using predetermined criteria, and appropriate articles were retrieved: abstracts with no relevance, no personal data, no information about donors or with already published data were excluded. For morbidity studies, we only included studies using the validated 5-tier Clavien grading [11] . Finally, we obtained 43 appropriate articles about morbidity, 15 about mortality and 6 regarding morbidity and mortality (Fig. 1) . The study design and results are summarized in Tables III and IV .
MORTALITY
According to our search strategy, we identified 21 original articles regarding the mortality of living donors after hepatectomy (Fig. 1 ). These studies included 23 patients who died after hepatectomy for donation, between 1999 and 2017. Table III summarizes all living donor deaths after right living donor donation documented by at least one publication. The major cause of death was postoperative sepsis: 7/23 (30%) of donor deaths.
Although the mortality after right hepatectomy for donation is low (0.3 to 0.5 %), death of a donor remains a tragedy for the families and transplant teams [2, 12, 13] . In 2006, the team of Paul Brousse Hospital published an opinion survey of health professionals (surgeons, physicians, nurses, aides and secretaries) on LDLT among adults from the same family [14] . In this series, the acceptable mortality rate for the donor was around 4%, except among internists (0.7%). These rates were all higher than the actual mortality rates reported in the literature (Table IV) . The authors concluded that the psychological involvement of transplant teams, although very strong in these conditions, should not be an obstacle to the development of this technique. In 2006, Trotter et al. [15] collected data on all deaths after hepatectomy for donation. Of the 4,598 LDLT in the United States and Europe, 13 donor deaths and 1 permanent vegetative state were directly related to the surgery. Among the deceased donors, 9 had a right lobectomy, while a single donor had a left lobectomy. For 3 patients, the lobe removed was unspecified. In 2008, Ringe et al. [13] compiled all cases of death reported or known in the world (publications, conferences, communications, personal conversations). This study identified 33 liver donor deaths including 3 after rescue transplantation; only 12 deaths were published in detail. The risk of death was directly proportional to the quantity of parenchyma resected: this mortality rate was up to 0.5% after right hepatectomy and from 0.1 to 0.3% after left hepatectomy. These results were confirmed by a series focused on right hepatectomy for tumors. In 2007, Truant et al. [3] reported the results of 31 extended right hepatectomies in non-cirrhotic liver, and concluded that the ratio of remnant liver volume to body weight is more relevant than the ratio of remnant liver volume to total liver volume in predicting postoperative liver failure and death. Patients with an anticipated remnant liver volume of <0.5% of the body weight were at considerable risk for postoperative mortality.
More recently, Muzaale et al. [2] reported the mortality rates and hepatocellular insufficiency after donation of part of the liver in the United States. Of the 4,111 LDLTs performed in the United States between 1994 and 2011, 7 donors died (4 after the removal of the right lobe, 1 of the left liver and 2 of the left lobe) and 4 other had liver failure in the postoperative period (3 of which required a transplantation). Significant progress has been made worldwide since the first LDLT, but this technique remains at risk for the donor. We identified 23 deaths between 1999 and 2017, and this number is probably higher, taking into account unpublished donor mortality. Centers with unreported deaths should submit these outcomes to the liver transplantation community to provide a better estimate of donor death rate. Furthermore, despite our research we have not found any recorded donor death after 2010, which raises the problem of inhomogeneous publication of worldwide data.
MORBIDITY
Removal of the right liver from a healthy donor is subject to significant morbidity. Indeed, the reported morbidity varied from 10% to 78.3% (Table IV) .
In 2002, Beavers et al. [16] compiled all outcome studies after donation of the right liver. Of the 211 publications dealing with this subject, the authors reported 12 studies with detailed results on postoperative complications. The overall morbidity rate was 31% (54 events in 174 donors) in this report [16] . However, the definition of complications is not standardized between different studies, which may lead to an underestimation of morbidity. In 2007, Yi et al. [17] The morbidity rate was correlated to the amount of liver tissue removed. The reports of the majority of transplant centers in Europe, Asia and the United States indicated that the rate of post-operative complications is higher after a right hepatectomy [18] than after a left hepatectomy especially regarding biliary leakage [16, [19] [20] [21] .
Moreover, some series showed that right hepatectomy for donation in high volume centers retains a significant morbidity [22] . In 2011, Azoulay et al. [23] reported the largest European single center series of hepatectomy for donation straight and a comprehensive assessment of complications classified according to the Clavien score [11] . In this series, less than half of the 91 donors, operated between 2000 and 2009, had a complication and a third of these were major complications (≥ grade III). It is interesting to note that in this series, as well as in other high-volume centers in Asia and the United States, there was no improvement in overall morbidity over time [2, [23] [24] [25] .
Recently, Belghiti et al. [26] reported the results of a casecontrol study comparing the effects of right hepatectomy in a living donor with those of a right hepatectomy for benign tumors that may explain this stable morbidity. The authors underlined that the complication rate was superior in a right hepatectomy for donation than for benign tumors. They concluded that living donor right hepatectomy caused a more severe loss of liver volume than right hepatectomy for benign tumors and that the liver regeneration effort remaining after hepatectomy was so important that it could have explained a greater vulnerability to postoperative complications. To measure and define the best achievable outcome after major hepatectomy, Rossler et al. [27] in 2016 proposed the analysis of a multicentric international series of 5202 hemi-hepatectomies from living donor. Indeed, analysis in living liver donors, with safety as the highest priority, offers the opportunity to define outcome benchmarks as the best possible results. Endpoints included postoperative morbidity measured by the ClavienDindo classification, the Comprehensive Complication Index (CCI), and liver failure according to different definitions. They reported that 12% of patients developed at least 1 complication: of these, 3.8% were major events (grade III, including 1 death), mostly related to biliary/bleeding events, and were twice higher after right hepatectomy. Lee et al. [28] recently reviewed prospectively collected data from the Korean Organ Transplantation Registry of all 832 live liver donors who underwent procedures between April 2014 and December 2015. They reported no deaths after living liver donation and overall, biliary and major complication (grade ≥ III) rates were 9.3%, 1.7% and 1.9%, respectively. Based on this literature review, the right liver removal in the living donor was burdened with significant morbidity even in experienced surgical teams [28] . The mortality of this procedure (which remains a major hepatic resection) cannot be reduced below 0.3% [2] . The decrease in morbidity and mortality in LDLT donors remains an important issue in the development of this technique in order to meet ethical requirements.
QUALITY OF LIFE
Beyond morbidity and mortality, the quality of life (QoL) of the donor after donation must also be considered. Indeed, living donors achieve no medical benefits and are exposed to the risk of major complications. Surprisingly, several studies showed that the QoL of donors was similar or even better than the reference population before donation [29] . The Physical Component Score decreased immediately after donation, then returned to baseline within 6 to 12 months, while the Mental Component Score remained comparable to that of normative population throughout the procedure [30] . In a study involving 19 living donors, Parolin et al. [31] showed that the donor's relationship to the recipient and to their families was improved after donation in all cases. Moreover, Bhatti et al. [32] showed that acceptable post-donation QoL was achieved and no significant difference in scores was observed between donors with and without surgical complications. This report is similar with those of Beavers et al. [33] , who reported that regardless of recipient outcome, 100% of donors would donate again and of Chang et al. [34] who reported that 87% of donors showed a willingness to re-donate. In contrast, Kousoulas et al. [35] reported that donors did not regret their decision to donate but development of postoperative donor complications and the postoperative recipient mortality had a negative effect on the Health-related QoL of donors. Evaluation of anxiety and depression 3 months after donation found no difference between donors and controls [36] . Psychiatric complications were found in 4.1% of donors in an Adult to Adult living donor liver transplantation study [37] . Among the 23 donor deaths described in the literature, 4 were due to suicide, raising questions about the donors QoL as well as their psychological follow-up after donation [15, 37] .
HOW TO REDUCE MORBIDITY AND MORTALITY IN LIVING DONORS?
To balance both a reduction of the risk for donors and to improve the outcome of the recipient, many strategies have been proposed. We have divided these different strategies into two groups: those aimed at reducing the amount of parenchyma harvested in the donor and those aimed at increasing the donor future remnant liver before the hepatectomy.
Reducing the amount of parenchyma harvested in the donor
These strategies comprised the limitation of the amount of parenchyma harvested in the donor and the control of the small for size syndrome (SFSS) risk in the recipient.
Operative strategies To avoid the right lobe donor risks, some teams started to use left lobe donation in adult patients. This procedure was first described by Hashikura in 1994 [6] . However, after the first successful graft, Tanaka et al. [38] reported in their early series of left lobe (LL) LDLT an 82.1% survival in patients with a graft to recipient weight ratio >0.8 but only 54.5% in those with a ratio <0.8. Furthermore, Kiuchi et al. [39] revealed inferior graft survival rates for smaller grafts which dropped off the LL graft development. Soejima et al. [40, 41] performed large single center studies which showed that the outcomes of LL LDLT were comparable with those of RL LDLT, although SFSS occurred more often in LL LDLT [2, 3] . To manage SFSS, they developed a specific approach to avoid excessive portal flow in the graft using hemi porto-caval shunt and splenectomy. They concluded that LL grafts should be considered as the first procedure except for patients with MELD score >30.
In order to deal with SFSS, dual graft LDLT was also introduced to obtain combined graft sufficiency. Xu et al. [42] reported 367 patients worldwide in 2015 and concluded that dual graft LDLT should be prudently performed in selected cases by surgeons of proven expertise when a single donation is unacceptable and a second living donor is available. However, the decision-making criteria need to be standardized and ethical concerns about involving a second living donor need to be addressed [42] .
Pharmacological treatment of SFSS A variety of experimental pharmacological treatment strategies have been described for the prevention of SFSS, based on the attenuation of portal shear stress and the enhancement of liver regeneration. The modulation of prostaglandin E1, nitric oxide, endothelin receptor A, adenosine 2A receptor, has been tested in animal models [43] . In 2016, Mohkam et al. [44] demonstrated the preventive effect of somatostatin by decreasing portal vein flow in a porcine model of SFSS [44] . Similar results were demonstrated in 90% of hepatectomized murine models using octreotide infusion [45] . Treatment of SFSS by somatostatin and propranolol has also been clinically tested and resulted in a favorable outcome [46] .
Increasing the donor future remnant liver before the hepatectomy
Pharmacological preconditioning In 2005, Malik et al. [47] proposed in an experimental study the administration of thyroid hormones (triiodothyronine, T3) to the donor rats, 10 days before hepatectomy (70% and 90% hepatectomy). The authors reported that the injection of T3 (bolus 4mg/kg) in rats was responsible for a trigger of hepatic regeneration and increased liver weight/body weight on day 10 associated with an increase in total liver volume. The 70% hepatectomy, 10 days after the preconditioning (T3), left in place a remnant liver volume larger than in non-pre-conditioned animals. After 90% hepatectomy, the preconditioned animals had better survival than nonpreconditioned (57% vs. 14%). However, the T3 injected doses were almost 2000 times the maximum dose in humans treated for thyroid insufficiency [48] . Despite these interesting results in terms of liver regeneration, it seems difficult to apply this preconditioning to humans considering the consequences, including cardiac, of an overdose of thyroid hormones.
Portal flow modulation in donors
Ischemic preconditioning by clamping the right pedicle for 10 minutes before living donation has been proposed to decrease the ischemia-reperfusion injury [49, 50] . Despite the involvement of anti-apoptotic molecular mechanisms, the authors did not report any clinical benefit in the donor or recipient.
Portal vein embolization is used in liver tumor treatment prior to major hepatectomy. The aim of this technique is to induce the atrophy of the ipsilateral liver and thus the hypertrophy of the future remnant liver before hepatectomy. Based on these results, some teams have developed reversible portal vein embolization to avoid liver atrophy [51] [52] [53] .
Nevertheless, reversible portal vein embolization failed to reduce liver atrophy and therefore, this technique cannot be used for living donor liver preconditioning [53] .
Khan et al. [54] studied the effects of partial portal vein ligation 8 weeks prior to hepatectomy on a murine model of partial hepatectomy. They observed that partial portal vein ligation prior to hepatectomy did not impair hepatic regeneration capacity, compared to sham animals.
Gregoire et al. recently identified that 20% stenosis of the portal vein of a hemi-liver in pigs induced a contralateral hypertrophy without atrophy of the ipsilateral liver [55] . This procedure might be an effective donor preconditioning in order to achieve a larger remnant liver in living donor without altering the future graft. Indeed, the 20% stenosis of the portal vein of a hemi-liver triggered the liver regeneration in the contralateral lobe (the future remnant liver of the donor) with cell proliferation equivalent to that observed after ligation or embolization of the portal vein.
CONCLUSIONS
Morbidity, mortality and donor QoL remain a major hindrance to the development of LDLT.
Donor morbidity and mortality are inevitable given the ultra-major nature of the donor operation, which is why the most serious ethical concerns in LDLT focus on the risks to the donor and relate to the principle of 'do no harm' . However, the state of research on the preconditioning of the donor allows an improvement in these parameters to be considered in the future, including donor preconditioning techniques (absorbable portal embolization, portal stenosis) and the use of the left liver associated with portal flow modulation in the recipient (portal banding).
Moreover, these techniques could represent a hope for countries in which LDLT is the only source of graft for organizational or cultural reasons.
Conflicts of interest:
The authors declare no conflicts of interest.
Authors, contribution: P.B., G.H., S.C. and A.P. collected and analyzed data; P.B. and G.H. wrote the manuscript; D.A. analyzed data, designed study and reviewed the manuscript; E.G. designed the study, collected data, reviewed the manuscript.
